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Pneumococcal Prevention Gets Older and Wiser
Anne Schuchat, MD
National Center for Immunization and Respiratory Diseases, Centers for Disease Control and 
Prevention, Atlanta, Georgia.
Pneumococcus, or Streptococcus pneumoniae, the “captain of the men of death” in the 
parlance of Sir William Osler, has killed millions of people while repeatedly frustrating 
clinicians, vaccine experts, and epidemiologists. The advent of effective antibiotics did not 
eliminate deaths from pneumococcal disease. Pneumococcal morbidity has remained 
substantial among the elderly population even though most have received the 23-valent 
pneumococcal polysaccharide vaccine (PPSV-23). Diagnostic tests for pneumonia are 
relatively insensitive and nonspecific.1 Thus, it is difficult to evaluate the efficacy of 
pneumococcal vaccines against pneumonias that do not lead to detectable bloodstream 
infection.
The Multivalent Polysaccharide Vaccines
Multivalent pneumococcal polysaccharide vaccines against 14 and later 23 capsular types 
were licensed in the United States in 1977 and 1983, respectively. The PPSV-23 was 
recommended for people 2 years or older with medical conditions putting them at high risk 
(eg, sickle cell disease) and for all those 65 years or older. Since the 1990s, when 
reimbursement for administration of pneumococcal vaccine was added to the Medicare 
beneficiary program, 60% to 70% of people in the United States 65 years or older have been 
vaccinated with PPSV-23.
The PPSV-23 provides moderate protection against invasive pneumococcal disease in people 
who are immunocompetent. It is unclear, however, whether polysaccharide vaccines have 
any effect on nonbacteremic pneumonia. Studies suggest that efficacy wanes over time and 
may decrease with age at vaccination. Disease incidence in adults increases with age. Before 
2014, the Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease 
Control and Prevention (CDC) recommended that people in their 65th year of life receive a 
single dose of PPSV-23 as well as an annual influenza vaccination.
Polysaccharide-Protein Conjugate Vaccines
Conjugation of capsular polysaccharide to carrier proteins in vaccines has led to improved 
immunologic response to pneumococcus in infants and young children compared with that 
induced by polysaccharide vaccines; it has also induced immunologic memory and reduced 
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acquisition of nasopharyngeal colonization. Since licensure in the United States in 2000, 
pneumococcal polysaccharide-protein conjugate vaccine has revolutionized the prevention 
of pneumococcal disease among children. Conjugate vaccines have high efficacy in young 
children against disease caused by the capsular types included in the vaccine and also reduce 
transmission of vaccine-type pneumococci from immunized children to others. The 7-valent 
(introduced in 2000) and the 13-valent (introduced in 2010) conjugate vaccine formulations 
dramatically reduced invasive and noninvasive pneumococcal infections in children2,3 and 
were estimated to prevent about 2 invasive infections indirectly for each 1 directly 
prevented.4
Although substantial reductions in invasive pneumococcal disease caused by the 7-valent 
types were seen in the elderly population following uptake of the 7-valent conjugate vaccine 
in children, nonbacteremic pneumococcal pneumonia has remained common in people older 
than 65 years.3 The advent of conjugate vaccines targeting more capsular types raised hope 
that direct vaccination of seniors might provide important additional benefits against 
pneumococcal pneumonias, including cases that are nonbacteremic. On December 30, 2011, 
the US Food and Drug Administration (FDA) approved a 13-valent pneumococcal conjugate 
vaccine (PCV-13), manufactured by Pfizer (Prevnar 13), for use in adults 50 years or older. 
Approval of PCV-13 for adults was based on detection of noninferior vaccine-induced 
antibody levels against vaccine types compared with levels observed following 
administration of PPSV-23. In June 2012, the ACIP voted to recommend PCV-13 use in 
adults at very high risk—eg, those with conditions such as human immunodeficiency virus 
infection, which increases risk of developing invasive pneumococcal disease more than 20-
fold.
However, the committee opted to delay consideration of PCV-13 recommendations for 
people 65 years or older, a much larger population, until 2 key pieces of additional data 
could be reviewed. First, the committee sought data on the effect that ongoing PCV-13 use in 
children was having on 13-valent type invasive pneumococcal infections in adults. Second, 
the committee awaited results of the CAPITA study—a randomized, placebo-controlled trial 
of PCV-13 efficacy against pneumococcal pneumonia in about 85 000 people 65 years or 
older conducted in the Netherlands from 2008 to 2013.5 Lack of similar randomized clinical 
trial data for pneumococcal polysaccharide vaccine in community-dwelling adults 65 years 
or older may have contributed to the long-standing controversy over the efficacy of this 
vaccine. In August 2014, the ACIP held an extraordinary meeting to consider the results of 
the CAPITA trial, which had yet to be published, and to deliberate on recommendations for 
routine use of PCV-13 among the elderly population.6 In this trial, the results of which were 
published in 2015,5 PCV-13 prevented 75% of vaccine-type invasive pneumococcal disease 
and 45% of vaccine-type nonbacteremic pneumonia. In the United States, an estimated 50 
000 hospitalizations occur annually in people 65 years or older for community-acquired 
pneumonia caused by the 13-valent type pneumococci.
Emergence of Vaccine Guidelines
The resulting ACIP guidance was issued by the CDC in September 20146; it was intended to 
provide the public and clinicians with updated practice recommendations in time for 
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vaccination in the fall of 2014 and as soon as possible after the CAPITA trial5 data were 
reviewed. The urgency arose from the approach of the winter season, when pneumonia and 
influenza rates peak, especially among seniors. The ACIP recommended a dose of the 
PCV-13 conjugate vaccine for all those 65 years or older followed by a dose of the PPSV-23 
formulation 6 to 12 months later. This recommendation was prompted by the continued 
occurrence of invasive disease related to pneumococcal types not covered by PCV-13 but 
covered by PPSV-23.
For people who never received a pneumococcal vaccine, the ACIP recommended that the 
conjugate vaccine should be administered first because the immune response is better than 
when the polysaccharide vaccine is given first. Most people 65 years or older have already 
received the polysaccharide vaccine, however. Therefore, to increase protection against 
nonbacteremic pneumonia, the ACIP recommended administration of the conjugate vaccine 
at least 12 months after the prior vaccination. On the basis of the CDC ACIP 
recommendations,6 the Centers for Medicare & Medicaid Services (CMS) revised the 
coverage of pneumococcal vaccines for Medicare beneficiaries, allowing reimbursement for 
2 doses (ie, 1 conjugate and 1 polysaccharide dose) when given at least 12 months apart.7
Continued Controversy Over Vaccine Guidelines
Some critics have stated that the CDC and the ACIP waited too long to recommend the use 
of PCV-13 in adults older than 65 years. Others have questioned whether PCV-13 should 
have been recommended for adults at all. And some were confused by the different dosing 
intervals in the 2014 recommendations.
This last concern has now been addressed. In June 2015, ACIP voted to set the interval 
between conjugate and polysaccharide vaccine doses for seniors at 12 months or more, 
regardless of order of receipt, consistent with the CMS reimbursement policy. The longer 
dosing interval for the conjugate vaccine followed by the polysaccharide vaccine is 
supported by evidence of lower reactogenicity, adequate immune response, and very small 
incremental risk of invasive disease caused by nonconjugate vaccine types during the 
additional 6 months between doses.8
The 2014-2015 winter was one of the worst in recent history for severe respiratory infections 
in the elderly population in the United States. The H3N2 influenza strains that had drifted 
away from the 2014-2015 influenza vaccine dominated, leading to the highest rates of 
laboratory-confirmed influenza hospitalizations among people 65 years or older observed 
since CDC’s surveillance of influenza hospitalizations began in 2005.9 The effectiveness of 
influenza vaccine against H3N2 influenza strains was very low.10 However, while influenza 
vaccines likely provided little benefit to the elderly population during the 2014-2015 flu 
season, those who had received a pneumococcal conjugate vaccine in addition to earlier 
polysaccharide vaccines were likely at lower risk for pneumococcal infections complicating 
influenza.
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Conclusions
The ACIP’s 2015 guidance is unlikely to end debate about optimal ways to defeat the 
pneumococcus. The ACIP will review its recommendations for the use of pneumococcal 
conjugate vaccine in the elderly population in 2018. Until the recommendations are 
reviewed, the evidence from the CAPITA trial5 suggests that widespread vaccination of 
older adults with the PCV-13 vaccine can prevent an important proportion of nonbacteremic 
pneumonias attributable to the pneumococcal types covered by the vaccine.
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